EndoPredict® is the only test that answers the following three important clinical questions…
… to optimize treatment for breast cancer patients.
EndoPredict is a second generation gene expression test – the newest type of test for predicting breast cancer recurrence. It is for post- and premenopausal women with early (non-metastatic) ER+, HER2- breast cancer with or without affected lymph nodes.
EndoPredict accurately measures the activity of specific genes that influence tumor growth, resulting in a 12-Gene Molecular Score. This allows conclusions about the likely outcome of the cancer (prognosis). Higher scores are associated with a higher risk.
Prolaris provides new information about your cancer that no other test can. The Prolaris test can determine just how unique and aggressive your prostate cancer truly is. Your Prolaris Score provides individualized information about your specific cancer to help you and your physician develop the appropriate treatment plan.
Prolaris provides answers to your most pressing questions
• What is the risk of my cancer spreading outside of the prostate?
• What is my risk to die from my prostate cancer?
• How should my cancer be treated - Am I a candidate for active surveillance? - Should I consider active treatment?
The Myriad Genetics MyChoice® CDx Plus test was developed and performance characteristics were determined by Myriad Genetic Laboratories, Inc. and in compliance to In-Vitro Diagnostic Device Directive (98/79/EC) and is CE marked. Myriad is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing. Myriad is compliant with multiple international standards including, ISO 13485:2016 and ISO 15189: 2012 as applicable.
Myriad myRisk® Hereditary Cancer is a 35-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on eight primary cancer sites.